The University of British Columbia

Nordion (canada) Inc.

Nordion Inc.

Bwxt Medical Ltd.

Chris Orvig

John H McNeill

Hamid R Hoveyda

Jere D Fellmann

John Hugh McNeil

Ying Zhou

Cara L Ferreira

Mike Adam

Eszter Boros

Eric William Price

Marco Melchior

Mark P Lowe

Eric W Price

Cara Lee Ferreira

A bifunctional chelating agent of the formula (I): wherein the variables R, R, Q, Qand M are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.

Bifunctional chelating agents

Pharmaceutical compositions of vanadium biguanide complexes, and methods of use, are provided for the treatment of hyperglycemia and related disorders, e.g. hypertension, obesity, and lipid disturbances. The pharmaceutically active complexes of the invention comprise a biguanide chelant, preferably a 1-substituted biguanide chelant, capable of chelating vanadium to form a six-membered unsaturated vanadium-containing ring. The vanadium of the complex is coordinated with oxygen, sulphur or nitrogen, particularly oxygen coordinated. The complexes are formulated with a physiologically acceptable carrier. In a preferred embodiment, the complexes are formulated for oral administration.

Pharmaceutical compositions of vanadium biguanide complexes and their use

Organic complexes of vanadium are provided, having the general structure VL,, where V is vanadium(III) and L is a monoprotic bidentate ligand that forms a five-membered, unsaturated vanadium containing ring, having vanadium coordinating oxygen or sulfur ring heteroatoms, and where the vanadium containing ring is fused to a six-membered heterocyclic ring. Preferably L is a hydroxypyrone or a hydroxypyridinone. The complexes have a number of uses, including the treatment of elevated blood glucose and related disorders, treatment of proliferative disorders, etc.

Organic vanadium (III) complexes and their use

The invention relates to novel chelating ligands which incorporate a tripodal backbone. More particularly, the invention pertains to novel tripodal ligands which form coordination compounds with a variety of metal ions, particularly, but not exclusively, trivalent metal ions and lanthanide metal ions, which are useful in nuclear medicine. A novel amine phosphinate tripodal ligand, a chelating ligand and a process therefor involving a metal ion and particularly a trivalent metal ion of the group 13 metals and the rare earths. The process comprises complexing Tc or Re or any one of the group 13 metals, Al, Ga and In, and any one of the rare earths, Sc, Y, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Th, Dy, Ho, En, Tm, Yb and Lu, with an amine phosphinate tripodal ligand.

Chelating ligands having a tripodal backbone

There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid, maltol and ethyl maltol.

Vanadium compounds in the treatment of elevated blood sugar levels

Vanadium compositions

There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid and maltol.

Method of suppressing appetite with vanadium complexes

Methods of treating hypertension with vanadium compositions

Bis(maltolato)oxovanadium compositions for the treatment of elevated

A pharmaceutical composition useful for lowering blood sugar and suppressing appetite in mammals. The composition comprises compounds of a formula selected from VOL.sub.2 or VO(OR)L.sub.2 in which L is a bidentate monoprotic ligand and R is an organic group. The composition includes a pharmaceutically acceptable carrier. The invention also provides a method of lowering blood sugar and suppressing appetite in a mammal that comprises administering to the mammal a compound of the above formula.

Complexed vanadium for the treatment of diabetes mellitus

Growing community of inventors

Vancouver, Canada

Chris Orvig